Vinblastine Infusion in Non-Hodgkin's Lymphomas: Lack of Total Cross-Resistance with Vincristine
作者:
JacksonDon V.,
SpurrCharles L.,
CaponeraM. E.,
WhiteD R.,
MussH. B.,
PavyM D.,
SartianoG P.,
ZekanP J.,
HireE A.,
期刊:
Cancer Investigation
(Taylor Available online 1987)
卷期:
Volume 5,
issue 6
页码: 535-539
ISSN:0735-7907
年代: 1987
DOI:10.3109/07357908709020312
出版商: Taylor&Francis
数据来源: Taylor
摘要:
AbstractHistorically, vinblastine given by intravenous bolus injection has not been an effective treatment for non-Hodgkin's lymphomas; vincristine has displayed greater activity. Also, vinblastine has generally been considered to be cross-resistant with vincristine in such patients. In an attempt to overcome these obstacles, a protracted infusion of vinblastine was administered (0.5–1.5 mg/m2per day for 5 days) and repeated every 3 weeks. Partial responses were observed in 4 of 29 (14%) patients with a variety of non-Hodgkin's lymphoma lasting 2.4, 2.4, 5.5, and 9.0 months. Just prior to treatment the responding patients had received and eventually become refractory to vincristine. These data show a lack of total cross-resistance between vinblastine and vincristine which might have important therapeutic implications in this disease.
点击下载:
PDF (357KB)
返 回